---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-001679"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2023-03-22T23:59:59+00:00"
generated_at: "2026-06-17T21:17:23.216145+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Phio Pharmaceuticals reports 2022 net loss of $11.5M and provides pipeline updates

## Summary
- Cash at Dec 31, 2022: $11.8M, down from $24.1M a year earlier; funds operations through Q4 2023.
- Net loss of $11.5M ($10.10/share) vs $13.3M ($12.43/share) in 2021; R&D expenses fell 21% to $7.0M.
- DMC recommended proceeding to second cohort of PH-762 Phase 1b for advanced melanoma after no safety issues.
- FDA cleared partner AgonOx to start Phase 1 ACT trial with PH-762 for solid tumors; PH-894 IND-enabling studies complete.
- Robert Bitterman appointed President and CEO (previously interim CEO); Nasdaq compliance regained after reverse split.

## SEC filing metadata
- accession: 0001683168-23-001679
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2023-03-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000168316823001679/0001683168-23-001679-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000168316823001679/phio_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-001679
- JSON: https://secwatch.observer/filing/0001683168-23-001679.json
- Plain text: https://secwatch.observer/filing/0001683168-23-001679.txt

## Key facts
- Earnings Releases
  Phio Pharmaceuticals Corp. reported the year ended December 31, 2022 results: net income approximately $11.5 million, or $10.10 per share, EPS $10.10 per share.
  - Period: the year ended December 31, 2022
  - Net income: approximately $11.5 million, or $10.10 per share
  - EPS: $10.10 per share
  - Result: reported results
  source text: Net loss decreased 14% to approximately $11.5 million, or $10.10 per share, for the year ended December 31, 2022, compared with $13.3 million, or $12.43 per share, for the year ended December 31, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1533040/000168316823001679/0001683168-23-001679-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.